CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


CA Cancer J Clin 1996; 46:46
doi: 10.3322/canjclin.46.1.46
© 1996 American Cancer Society
This Article
Right arrow Full Text (PDF) Freely available
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Green, D. M.
Right arrow Articles by Thomas, P. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Green, D. M.
Right arrow Articles by Thomas, P. R.

CA: A Cancer Journal for Clinicians, Vol 46, Issue 1 46-63, Copyright © 1996 by American Cancer Society


ARTICLES

Wilms tumor

D. M. Green, G. J. D'Angio, J. B. Beckwith, N. E. Breslow, P. E. Grundy, M. L. Ritchey and P. R. Thomas
Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, New York, USA.

Wilms tumor is the most common primary malignant renal tumor of childhood, representing about six percent of all childhood cancers in the United States. Developments in surgery, radiation therapy, and chemotherapy have led to a dramatic change in the prognosis for most patients, and Wilms tumor has become a paradigm for multimodal treatment of a pediatric malignant solid tumor. The authors review the progress made in the diagnosis and management of children with Wilms tumor.


This article has been cited by other articles:


Home page
Cancer Res.Home page
J. S. Dome, S. Chung, T. Bergemann, C. B. Umbricht, M. Saji, L. A. Carey, P. E. Grundy, E. J. Perlman, N. E. Breslow, and S. Sukumar
High Telomerase Reverse Transcriptase (hTERT) Messenger RNA Level Correlates with Tumor Recurrence in Patients with Favorable Histology Wilms' Tumor
Cancer Res., September 1, 1999; 59(17): 4301 - 4307.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by American Cancer Society.